Search results
Search for "antitumor activity" in Full Text gives 67 result(s) in Beilstein Journal of Organic Chemistry.
Streamlined modular synthesis of saframycin substructure via copper-catalyzed three-component assembly and gold-promoted 6-endo cyclization
- Asahi Kanno,
- Ryo Tanifuji,
- Satoshi Yoshida,
- Sota Sato,
- Saori Maki-Yonekura,
- Kiyofumi Takaba,
- Jungmin Kang,
- Kensuke Tono,
- Koji Yonekura and
- Hiroki Oguri
Beilstein J. Org. Chem. 2025, 21, 226–233, doi:10.3762/bjoc.21.14
- antitumor activity, triggered by DNA alkylation [6][7][8]. The aminonitrile/hemiaminal at C21 generates an iminium cation while releasing a cyanide or a hydroxy group under physiological conditions. This iminium cation facilitates nucleophilic attack by guanine residues in the minor groove of the GC-rich
Graphical Abstract
Figure 1: Representative bis-tetrahydroisoquinoline (THIQ) alkaloids and their analogues. Oxygen atoms on bot...
Scheme 1: Strategies for the construction of the pentacyclic core scaffold of saframycin A (1). (a) Biosynthe...
Scheme 2: Streamlined synthesis of the substructure 14 for saframycins 1 within just four steps in overall 29...
Figure 2: UV–vis absorption (gray solid line), the emission spectrum (blue solid line), and the corresponding...
N-Glycosides of indigo, indirubin, and isoindigo: blue, red, and yellow sugars and their cancerostatic activity
- Peter Langer
Beilstein J. Org. Chem. 2024, 20, 2840–2869, doi:10.3762/bjoc.20.240
- moiety. It was demonstrated that 3-alkylideneoxindole-N-glycosides 46 show a significant antitumor activity against melanoma human cell lines SK-Mel-147 and A-375 [46]. As mentioned above, the death ligand TRAIL is a promising strategy for cancer treatment. Unfortunately, melanoma cells show both
- ][57]. The presence of an additional nitrogen atom in the isoindigo moiety proved to be important for an improved antitumor activity. In vitro antiproliferative activities of these compounds were tested against the human buccal carcinoma cell line (KB) and human myeloid leukaemia cell lines (K562, HL60
Graphical Abstract
Scheme 1: Structures of indigo (1a), indirubin (2a) and isoindigo (3a).
Scheme 2: Structures of akashins A–C.
Scheme 3: Synthesis of 5b. Reagents and conditions: i) TMSOTf, 4 Å MS, CH2Cl2, −20 °C, 1.5 h, then 20 °C, 8–1...
Scheme 4: Synthesis of 7c. Reagents and conditions: i) TMSOTf, 4 Å MS, CH2Cl2, −18 °C, 3 h; then: TMSOTf, 4 Å...
Scheme 5: Synthesis of 1d. Reagents and conditions: i) chloroacetic acid, Na2CO3, reflux, 6 h; ii) Ac2O, NaOA...
Scheme 6: Synthesis of 10e. Reagents and conditions: i) p-TsOH·H2O, acetonitrile, MeOH, 1 d; ii) NIS, PPh3, D...
Scheme 7: Synthesis of akashins A–C. Reagents and conditions: i) TMSOTf, 4 Å MS, CH2Cl2, −18 to 20 °C, 15 h; ...
Scheme 8: Synthesis of 5d. Reagents and conditions: i) KMnO4, AcOH, high-power-stirring (12.000 rot/min), 20 ...
Scheme 9: Possible mechanism of the formation of 5c.
Scheme 10: Synthesis of 7d. Reagents and conditions: i) 1) CH2Cl2, 2) Me3SiI, 20 °C, 30 min, 3) 0 °C, 30 min, ...
Scheme 11: Synthesis of α-15b. Reagents and conditions: i) 1) CH2Cl2, 2) Me3SiI, 20 °C, 30 min, 3) 0 °C, 30 mi...
Scheme 12: Synthesis of isatin-N-glycosides 16a–f. Reagents and conditions: i) PhNH2, EtOH, 20 °C, 12 h; ii) Ac...
Scheme 13: Synthesis of 17–21. Reagents and conditions: i) Na2CO3, MeOH, 20 °C, 4 h.
Scheme 14: Synthesis of indirubin-N-glycosides α-17a and α-17b.
Scheme 15: Synthesis of β-17f. Reagents and conditions: i) 1) Na2CO3, MeOH, 20 °C, 4 h, 2) Ac2O/pyridine 1:1, ...
Scheme 16: Synthesis of β-24a. Reagents and conditions: i) n-PrOH, H2O, formic acid (buffer, 100 mM), 2 h, 65 ...
Scheme 17: Synthesis of isatin-N-glycosides 23b–g and 24b–g.
Scheme 18: Synthesis of β-29a,b. Reagents and conditions: i) EtOH, 20 °C, 12 h; ii) DDQ, dioxane, 20 °C, 12 h;...
Scheme 19: Synthesis of β-31a. Reagents and conditions: i) Na2SO3, dioxane, H2O, 110 °C, 2 d; ii) piperidine, ...
Scheme 20: Synthesis of 33a–d. Reagents and conditions: i) Ac2O, AcOH, NaOAc, 80 °C, 1 h; ii) 1) NaOMe, anhydr...
Scheme 21: Indirubins 34 and 35.
Scheme 22: Synthesis of 36f. Reagents and conditions: i) NaOH, H2O, 20 °C, 5 h; ii) HCl, NaNO2, H2O, −14 °C; i...
Scheme 23: Synthesis of 38a–h. Reagents and conditions: i) 1) 0.1 equiv NaOMe, MeOH, 20 °C, 15–20 min, 2) HOAc...
Scheme 24: Synthesis of 40a–h. Reagents and conditions: i) method A: EtOH/THF, cat. KOt-Bu, 20 °C, 3–4.5 h; me...
Scheme 25: Synthesis of 41a–d. Reagents and conditions: i) Ac2O, AcOH, NaOAc, 80 °C, 1 h.
Scheme 26: Synthesis of 41e. Reagents and conditions: i) AcOH, NaOAc, 110 °C, 24 h.
Scheme 27: Synthesis of E-β-43a–e and E-β-44a,b. Reagents and conditions: i) 1) NEt3, EtOH, 20 °C, 12 h, 2) DM...
Scheme 28: Synthesis of E-43f. Reagents and conditions: i) Na2CO3, MeOH, 20 °C, 6–24 h.
Scheme 29: Synthesis of 46a–m. Reagents and conditions: i) NEt3 (1 equiv), EtOH, 20 °C, 6–10 h; ii) MsCl, NEt3...
Scheme 30: Synthesis of 48a–d. Reagents and conditions: i) AcOH/Ac2O, NaOAc, 60 °C, 3–4 h.
Scheme 31: Synthesis of 48e. Reagents and conditions: i) NaOAc, AcOH, 110 °C, 24 h.
Scheme 32: Synthesis of β-49a,b. Reagents and conditions: i) AcOH/Ac2O, NaOAc, 60 °C, 3–4 h.
Scheme 33: Synthesis of β-54a,b. Reagents and conditions: i) 1) NaH, DMF, 0 °C, 15 min, 2) β-51a,b, 20 °C, 3 h...
Scheme 34: Synthesis of 54c–l. The yields refer to the yields of the first and second condensation step for ea...
Scheme 35: Synthesis of 57a–c and 58a–d. Reagents and conditions: i) HCl (conc.), AcOH, reflux, 24 h; ii) 1) B...
Scheme 36: Synthesis of 59a–e and 60a–e. Reagents and conditions: i) P(NEt2)3 (1.1 equiv), CH2Cl2, −78 °C to 2...
Scheme 37: Synthesis of 61a–d and 62a–d. Reagents and conditions: i) P(NEt2)3 (1.1 equiv), CH2Cl2, −78 °C to 2...
Scheme 38: Synthesis of β-64a–e and α-64a. Reagents and conditions: i) AcOH, Ac2O, NaOAc, 90 °C, 6 h.
Scheme 39: Synthesis of β-72a. Reagents and conditions: i) 66, EtOH, 20 °C, 12 h; ii) DDQ, dioxane, 20 °C, 12 ...
Scheme 40: Synthesis of β-72b.
Scheme 41: Synthesis of β-74a–c. Reagents and conditions: i) AcOH, Ac2O, NaOAc, 130 °C, 2 d.
Scheme 42: Synthesis of β-77. Reagents and conditions: i) 1) NEt3, EtOH, 20 °C, 12 h, 2) DMAP, NEt3, MsCl, 0 °...
Scheme 43: Synthesis of β-81a–f and β-80g. Reagents and conditions: i) AcOH, 80 °C, 1–3 h; ii) benzene, PTSA, ...
Scheme 44: Synthesis of 84a. Reagents and conditions: i) benzene, AlCl3, 20 °C, 10 min; ii) MeOH, NaOMe, 12 h,...
Scheme 45: Synthesis of 84b–l. The yields refer to the yields of the condensation and the deprotection step fo...
Synthesis, electrochemical properties, and antioxidant activity of sterically hindered catechols with 1,3,4-oxadiazole, 1,2,4-triazole, thiazole or pyridine fragments
- Daria A. Burmistrova,
- Andrey Galustyan,
- Nadezhda P. Pomortseva,
- Kristina D. Pashaeva,
- Maxim V. Arsenyev,
- Oleg P. Demidov,
- Mikhail A. Kiskin,
- Andrey I. Poddel’sky,
- Nadezhda T. Berberova and
- Ivan V. Smolyaninov
Beilstein J. Org. Chem. 2024, 20, 2378–2391, doi:10.3762/bjoc.20.202
- derivatives are used as ligands in the synthesis of metal complexes (Ni(II), Pd(II), Pt(II), Cu(I), Ag(I) etc.) exhibiting antibacterial and antitumor activity [34]. In most cases, polyfunctional catechol thioethers were obtained by Michael reaction via the interaction of o-, p-benzoquinone and the
Graphical Abstract
Scheme 1: Synthesis of catechol-containing compounds 1–9.
Figure 1: The X-ray structure of catechol 5 (the thermal ellipsoids of 50% probability). The hydrogen atoms e...
Figure 2: The X-ray structures of catechols 6 (a) and 8 (b) (the thermal ellipsoids of 50% probability). The ...
Figure 3: Fragment of the pack of catechol 5 in crystal (the H-bonds and π–π interactions are shown as dotted...
Figure 4: The interactions in pair of independent molecules A and B of 6 in crystal 6·0.5CH3CN (the H-bonds a...
Figure 5: Fragment of the pack of catechol 8 in crystal (the H-bonds and π–π interactions are shown as dotted...
Scheme 2: Electrochemical transformations of compounds 1–3.
Figure 6: The CV curve of 2 at the potential range from −0.50 to 1.60 V (CH3CN, GC electrode, Ag/AgCl/KCl(sat...
Figure 7: The CV curves of 3 at the potential ranges from –0.5 to 1.2 V (curve 1); from –0.5 to 2.0 V (curve ...
Figure 8: The CV curves of 7 at the potential ranges from –0.5 to 1.3 V (curve 1); from –0.5 to 1.8 V (curve ...
Scheme 3: Proposed mechanism of an electrooxidation of compounds 6–8.
Figure 9: The level of TBARS in rat liver homogenates in vitro, in the presence of compounds 1–9, Trolox, and...
Natural resorcylic lactones derived from alternariol
- Joachim Podlech
Beilstein J. Org. Chem. 2024, 20, 2171–2207, doi:10.3762/bjoc.20.187
Graphical Abstract
Figure 1: Examples of compounds covered in this review categorized in six sub-classes (see text).
Figure 2: Examples of compounds not covered in this review.
Figure 3: Wrongly assigned and thus obsolete structures (details will be discussed in the respective chapters...
Figure 4: Alternariol with the correct IUPAC numbering and an occasionally used numbering based on the biphen...
Figure 5: Alternariol O-methyl ethers.
Figure 6: Alternariol O-glycosides.
Figure 7: Alternariol O-acetates and O-sulfates.
Figure 8: 2-Hydroxy- and 4-hydroxy-substituted alternariol and its O-methyl ethers.
Figure 9: Chloro- and amino-substituted alternariol and its O-methyl ethers.
Figure 10: Presumed alternariol derivatives with non-canonical substitution pattern.
Figure 11: Alternariol derivatives with the 1-methyl group hydroxylated.
Figure 12: Verrulactones: pseudo-dimeric derivatives of altertenuol and related compounds.
Figure 13: Biaryls formed by reductive lactone opening and/or by decarboxylation.
Figure 14: Altenuene and its diastereomers.
Figure 15: 9-O-Demethylated altenuene diastereomers.
Figure 16: Acetylated and methylated altenuene diastereomers.
Figure 17: Altenuene diastereomers modified with lactic acid, pyruvic acid, or acetone.
Figure 18: Neoaltenuene and related compounds.
Figure 19: Dehydroaltenusin and its derivatives.
Scheme 1: Equilibrium of dehydroaltenusin in polar solvents [278].
Figure 20: Further quinoid derivatives.
Figure 21: Dehydroaltenuenes.
Figure 22: Complex aggregates containing dehydroaltenuene substructures and related compounds.
Figure 23: Dihydroaltenuenes.
Figure 24: Altenuic acids and related compounds.
Figure 25: Cyclopentane- and cyclopentene-fused derivatives.
Figure 26: Cyclopentenone-fused derivatives.
Figure 27: Spiro-fused derivatives and a related ring-opened derivative.
Figure 28: Lactones-fused and lactone-substituted derivatives.
Scheme 2: Biosynthesis of alternariol [324].
Scheme 3: Biosynthesis of alternariol and its immediate successors with the genes involved in the respective ...
Scheme 4: Presumed formation of altenuene and its diastereomers and of botrallin.
Scheme 5: Presumed formation of altenuic acids and related compounds.
Scheme 6: A selection of plausible biosynthetic paths to cyclopenta-fused metabolites. (No stereochemistry is...
Scheme 7: Biomimetic synthesis of alternariol (1) by Harris and Hay [66].
Scheme 8: Total synthesis of alternariol (1) by Subba Rao et al. using a Diels–Alder approach [34].
Scheme 9: Total synthesis of alternariol (1) using a Suzuki strategy by Koch and Podlech [62], improved by Kim et...
Scheme 10: Total synthesis of alternariol (1) using an intramolecular biaryl coupling by Abe et al. [63].
Scheme 11: Total synthesis of altenuene (54) and isoaltenuene (55) by Podlech et al. [249].
Scheme 12: Total synthesis of neoaltenuene (69) by Podlech et al. [35].
Scheme 13: Total synthesis of TMC-264 (79) by Tatsuta et al. [185].
Scheme 14: Total synthesis of cephalosol (99) by Koert et al. [304].
Green and sustainable approaches for the Friedel–Crafts reaction between aldehydes and indoles
- Periklis X. Kolagkis,
- Eirini M. Galathri and
- Christoforos G. Kokotos
Beilstein J. Org. Chem. 2024, 20, 379–426, doi:10.3762/bjoc.20.36
- towards the production of 2OHE1, thus reducing the risk for estrogen-sensitive cancers, especially in combination with tamoxifen, which is an estrogen receptor modulator used in the treatment of breast cancer [4]. BIMs increase the efficacy of the antitumor activity of tamoxifen and reduce the side
Graphical Abstract
Scheme 1: Examples of BIMs used for their medicinal properties.
Scheme 2: Mechanisms for the synthesis of BIMs using protic or Lewis acids as catalysts.
Scheme 3: Synthesis of bis(indolyl)methanes using DBDMH.
Scheme 4: Competition experiments and synthesis of bis(indolyl)methanes using DBDMH.
Scheme 5: Proposed mechanism for formation of BIM of using DBDMH.
Scheme 6: Synthesis of bis(indolyl)methanes using I2.
Scheme 7: General reaction mechanism upon halogen bonding.
Scheme 8: Synthesis of bis(indolyl)methanes using I2, introduced by Ji.
Scheme 9: Synthesis of bis(indolyl)methanes using Br2 in CH3CN.
Scheme 10: Βidentate halogen-bond donors.
Scheme 11: Synthesis of bis(indolyl)methanes using bidentate halogen-bond donor 26.
Scheme 12: Proposed reaction mechanism.
Scheme 13: Synthesis of bis(indolyl)methanes using iodoalkyne as catalyst.
Scheme 14: Proposed reaction mechanism.
Scheme 15: Optimized reaction conditions used by Ramshini.
Scheme 16: Activation of the carbonyl group by HPA/TPI-Fe3O4.
Scheme 17: Synthesis of BIMs in the presence of nanoAg-Pt/SiO2-doped silicate.
Scheme 18: Mechanism of action proposed by Khalafi-Nezhad et al.
Scheme 19: Activation of the carbonyl group by the Cu–isatin Schiff base complex.
Scheme 20: Optimum reaction conditions published by Jain.
Scheme 21: Organocatalytic protocol utilizing nanoparticles introduced by Bankar.
Scheme 22: Activation of the carbonyl group by the AlCl3·6H2O-SDS-SiO2 complex.
Scheme 23: Optimal reaction conditions for the aforementioned nano-Fe3O4 based catalysts.
Scheme 24: Nanocatalytic protocol proposed by Kaur et al.
Scheme 25: Microwave approach introduced by Yuan.
Scheme 26: Microwave approach introduced by Zahran et al.
Scheme 27: Microwave irradiation protocol introduced by Bindu.
Scheme 28: Silica-supported microwave irradiation protocol.
Scheme 29: Proposed mechanism for formation of BIM by Nongkhlaw.
Scheme 30: Microwave-assisted synthesis of BIMs catalyzed by succinic acid.
Scheme 31: Proposed mechanism of action of MMO-4.
Scheme 32: Catalytic approach introduced by Muhammadpoor-Baltork et al.
Scheme 33: Reaction conditions used by Xiao-Ming.
Scheme 34: Ultrasonic irradiation-based protocol published by Saeednia.
Scheme 35: Pyruvic acid-mediated synthesis of BIMs proposed by Thopate.
Scheme 36: Synthesis of BIMs using [bmim]BF4 or [bmim]PF6 ionic liquids.
Scheme 37: Synthesis of BIMs utilizing In(OTf)3 in octylmethylimidazolium hexafluorophosphate as ionic liquid.
Scheme 38: FeCl3·6H2O-catalyzed synthesis of BIMs with use of ionic liquid.
Scheme 39: Synthesis of BIMs utilizing the [hmim]HSO4/EtOH catalytic system.
Scheme 40: Synthesis of BIMs utilizing acidic ionic liquid immobilized on silica gel (ILIS-SO2Cl).
Scheme 41: The [bmim][MeSO4]-catalyzed reaction of indole with various aldehydes.
Scheme 42: The role of [bmim][MeSO4] in catalyzing the reaction of indole with aldehydes.
Scheme 43: Synthesis of BIMs utilizing FeCl3-based ionic liquid ([BTBAC]Cl-FeCl3) as catalyst.
Scheme 44: Synthesis of BIMs using [Msim]Cl at room temperature.
Scheme 45: [Et3NH][H2PO4]-catalyzed synthesis of bis(indolyl)methanes.
Scheme 46: PILs-catalyzed synthesis of bis(indolyl)methanes.
Scheme 47: FSILs-mediated synthesis of bis(indolyl)methanes.
Scheme 48: Possible “release and catch” catalytic process.
Scheme 49: Synthesis of bis(indolyl)methanes by [DABCO-H][HSO4].
Scheme 50: Synthesis of bis(indolyl)methanes by [(THA)(SO4)].
Scheme 51: Synthesis of BBSI-Cl and BBSI-HSO4.
Scheme 52: Synthesis of BIMs in the presence of BBSI-Cl and BBSI-HSO4.
Scheme 53: Chemoselectivity of the present method.
Scheme 54: Synthesis of BIMs catalyzed by chitosan-supported ionic liquid.
Scheme 55: Proposed mechanism of action of CSIL.
Scheme 56: Optimization of the reaction in DESs.
Scheme 57: Synthesis of BIMs using ChCl/SnCl2 as DES.
Scheme 58: Synthesis of BIMs derivatives in presence of DES.
Scheme 59: BIMs synthesis in choline chloride/urea (CC/U).
Scheme 60: Flow chemistry-based synthesis of BIMs by Ley.
Scheme 61: Flow chemistry-based synthesis of BIMs proposed by Nam et al.
Scheme 62: Amino-catalyzed reaction of indole with propionaldehyde.
Scheme 63: Aminocatalytic synthesis of BIMs.
Scheme 64: Proposed mechanism for the aminocatalytic synthesis of BIMs.
Scheme 65: Enzymatic reaction of indole with aldehydes.
Scheme 66: Proposed mechanism for the synthesis of BIMs catalyzed by TLIM.
Scheme 67: Proposed reaction mechanism by Badsara.
Scheme 68: Mechanism proposed by D’Auria.
Scheme 69: Photoinduced thiourea catalysis.
Scheme 70: Proposed mechanism of photoacid activation.
Scheme 71: Proposed mechanism of action for CF3SO2Na.
Scheme 72: Proposed mechanism for the synthesis of BIMs by Mandawad.
Scheme 73: Proposed mechanism for the (a) acid generation and (b) synthesis of BIMs.
Scheme 74: a) Reaction conditions employed by Khaksar and b) activation of the carbonyl group by HFIP.
Scheme 75: Activation of the carbonyl group by the PPy@CH2Br through the formation of a halogen bond.
Scheme 76: Reaction conditions utilized by Mhaldar et al.
Scheme 77: a) Reaction conditions employed by López and b) activation of the carbonyl group by thiourea.
Scheme 78: Infrared irradiation approach introduced by Luna-Mora and his research group.
Scheme 79: Synthesis of BIMs with the use of the Fe–Zn BMOF.
Photochromic derivatives of indigo: historical overview of development, challenges and applications
- Gökhan Kaplan,
- Zeynel Seferoğlu and
- Daria V. Berdnikova
Beilstein J. Org. Chem. 2024, 20, 228–242, doi:10.3762/bjoc.20.23
- tinctoria plant. Like indirubins, the isoindigo derivatives were initially studied as potential therapeutics with pronounced antitumor activity [74]. More recently, advantageous charateristics of isoindigos for the applications in organic photovoltaics (OPV) [75] and optoelectronics [76] were revealed. The
Graphical Abstract
Figure 1: Precursors used in the synthesis of indigo [4].
Figure 2: a) Intramolecular (a = 2.26 Å) and intermolecular (b = 2.11 Å) hydrogen bonds in indigo, b) crystal...
Figure 3: Bond length in the indigo molecule obtained from the single crystal X-ray analysis [12], the typical bo...
Figure 4: The structure of the indigo chromophore (H-chromophore, highlighted in blue), asterisk indicates th...
Figure 5: Influence of substituents in the benzene rings on the color of indigo derivatives.
Figure 6: a) E–Z photoisomerization of indigo and b) photoinduced proton transfer in the excited state, aster...
Figure 7: Structures of indigo derivatives discussed in this review.
Figure 8: Photoswitching of N,N'-diacetylindigo (9a) in CCl4 (c = 17.1 µM; cell length = 5.0 cm) irradiated w...
Figure 9: Photoisomerization of compound 18c upon irradiation with red light and schematic representation of ...
Figure 10: Schematic representation of indigo-type (left) and amide-type (right) resonances in N,N'-acetylindi...
Figure 11: Suggested intermediates for the double bond cleavage for the thermal relaxation of N,N'-diacylindig...
Figure 12: Zwitterionic resonance structures of Z-indigo.
Figure 13: Photos of crystalline N,N'-di(Boc)indigo 17a its solutions in 1) DMSO, 2) DMF, 3) N-methyl-2-pyrrol...
Figure 14: Structural isomers of indigo.
Figure 15: Photochromism of indirubin derivatives and supramolecular complexation of the E-isomers with Schrei...
Figure 16: Photoisomerization of the protonated isoindigo.
Synthesis and biological evaluation of Argemone mexicana-inspired antimicrobials
- Jessica Villegas,
- Bryce C. Ball,
- Katelyn M. Shouse,
- Caleb W. VanArragon,
- Ashley N. Wasserman,
- Hannah E. Bhakta,
- Allen G. Oliver,
- Danielle A. Orozco-Nunnelly and
- Jeffrey M. Pruet
Beilstein J. Org. Chem. 2023, 19, 1511–1524, doi:10.3762/bjoc.19.108
- (R3/R4). Compound C4 is the known compound O-methylfagaronine, which has previously been synthesized through a variety of methods [50][51][52]. The antileukemia activity, antitumor activity, and inhibition of reverse transcriptase of O-methylfagaronine (C4) have previously been explored [51][52][53
Graphical Abstract
Figure 1: Zones of inhibition for 1 mg of evaporated methanolic (MeOH) extracts from various parts of the A. ...
Scheme 1: General route to berberine variants, displaying the numbering system for the berberine ring.
Scheme 2: Synthesis of new berberine variants. Reductive amination to a secondary amine was followed by cycli...
Figure 2: X-ray crystal structures of the oxidation byproducts a) B4 (CCDC 2271457) and b) B6 (CCDC 2271458; ...
Scheme 3: Direct modification of the original berberine structure.
Scheme 4: Preparation of non-cyclic charged variants of B1.
Scheme 5: Partial reduction of compound B1 to B14.
Figure 3: Kirby–Bauer zones of inhibition for all variants B1–B14 compared to original berberine (B). Mean zo...
Scheme 6: Synthesis of the substituted 2-bromoaminonaphthalenes 9 and 10.
Scheme 7: Completion of the synthesis of variants C1–C4.
Figure 4: Kirby–Bauer zones of inhibition for variants C1–C4 compared to original chelerythrine (C). Mean zon...
Figure 5: Effects of original berberine and all variants against T84 human colon cancer cells. Cells were tre...
Figure 6: Effects of original chelerythrine and all variants against T84 human colon cancer. Cells were treat...
Synthesis of ether lipids: natural compounds and analogues
- Marco Antônio G. B. Gomes,
- Alicia Bauduin,
- Chloé Le Roux,
- Romain Fouinneteau,
- Wilfried Berthe,
- Mathieu Berchel,
- Hélène Couthon and
- Paul-Alain Jaffrès
Beilstein J. Org. Chem. 2023, 19, 1299–1369, doi:10.3762/bjoc.19.96
Graphical Abstract
Figure 1: Chemical structure of some natural ether lipids (ELs).
Figure 2: Synthesis of lyso-PAF and PAF from 1-O-alkylglycerol [64].
Figure 3: Synthesis of lyso-PAF from 1,3-benzylideneglycerol 3.1 [69].
Figure 4: A) Synthesis of the two enantiomers of octadecylglycerol (4.6 and 4.10) from ᴅ-mannitol (4.1); B) s...
Figure 5: Four-step synthesis of PAF 5.6 from (S)-glycidol [73].
Figure 6: Synthesis of 1-O-alkylglycerol A) from solketal, B) from ᴅ- or ʟ-tartaric acid and the intermediate ...
Figure 7: Synthesis of EL building blocks starting from substituted glycidol 7.1a–c [82].
Figure 8: Synthesis of PAF 8.5 by using phosphoramidite 8.2 [86].
Figure 9: Synthesis of oleyl-PAF 9.7 from ʟ-serine [88].
Figure 10: Synthesis of racemic analogues of lyso-PAF 10.8 and PAF 10.9 featuring a phenyl group between the g...
Figure 11: Synthesis of racemic deoxy-lyso-PAF 11.7 and deoxy-PAF 11.8 [91].
Figure 12: Synthesis of racemic thio-PAF 12.8 [93].
Figure 13: Racemic synthesis of 13.6 to illustrate the modification of the glycerol backbone by adding a methy...
Figure 14: Racemic synthesis of 14.5 as an illustration of the introduction of methyl substituents on the glyc...
Figure 15: Synthesis of functionalized sn-2-acyl chains of PC-EL; A) Steglich esterification or acylation reac...
Figure 16: Synthesis of racemic mc-PAF (16.3), a carbamate analogue of PAF [102].
Figure 17: A) Synthesis of (R)-17.2 and (S)-17.6 starting from (S)-solketal (17.1); B) synthesis of N3-PAF (17...
Figure 18: Modification of the phosphocholine polar head to produce PAF analogues [81].
Figure 19: Racemic PAF analogues 19.3 and 19.5 characterized by the absence of the phosphate group [107].
Figure 20: Synthesis of PIP3-PAF (20.7) [108].
Figure 21: Large-scale synthesis of C18-edelfosine (21.8) [116].
Figure 22: Synthesis of C16-edelfosine (22.10) starting from isopropylidene-ʟ-glyceric acid methyl ester (22.1...
Figure 23: Phosphocholine moiety installation by the use of chlorophosphite 23.2 as key reagent [119].
Figure 24: Synthesis of rac-1-alkyl-2-O-methylglycerol (AMG) [120].
Figure 25: Synthesis of stereocontrolled 1-alkyl-2-O-methyl glycerol 25.9 (AMG) from dimethyl ᴅ-tartrate [81].
Figure 26: A) Racemic synthesis of thioether 26.4 [129,130], B) structure of sulfone analogue 26.5 [129].
Figure 27: Stereocontrolled synthesis of C18-edelfosine thioether analogue 27.8 [118].
Figure 28: Synthesis of thioether 28.4 that include a thiophosphate function [134].
Figure 29: Synthesis of ammonium thioether 29.4 and 29.6 [135].
Figure 30: Synthesis of the N-methylamino analogue of edelfosine 30.6 (BN52211) [138].
Figure 31: Synthesis of 1-desoxy analogues of edelfosine; A) with a saturated alkyl chain; B) synthesis of the...
Figure 32: Stereocontrolled synthesis of edelfosine analogue (S)-32.8 featuring a C18:1 lipid chain [142].
Figure 33: Synthesis of edelfosine analogues with modulation of the lipid chain; A) illustration with the synt...
Figure 34: Synthesis of phospholipid featuring a carbamate function to link the lipid chain to the glycerol un...
Figure 35: Synthesis of sesquiterpene conjugates of phospho glycero ether lipids [148].
Figure 36: Racemic synthesis of methyl-substituted glycerol analogues 36.7 and 36.10: A) synthesis of diether ...
Figure 37: Racemic synthesis of ilmofosine (37.6) [155,156].
Figure 38: A) Stereoselective synthesis of 38.5 via a stereoselective hydroboration reaction; B) synthesis of ...
Figure 39: Racemic synthesis of SRI62-834 (39.6) featuring a spiro-tetrahydrofurane heterocycle in position 2 ...
Figure 40: Racemic synthesis of edelfosine analogue 40.5 featuring an imidazole moiety in sn-2 position [160].
Figure 41: Racemic synthesis of fluorine-functionalized EL: A) Synthesis of 41.6 and B) synthesis of 41.8 [161-163].
Figure 42: A) Synthesis of the β-keto-ester 42.6 that also features a decyl linker between the phosphate and t...
Figure 43: Synthesis of phosphonate-based ether lipids; A) edelfosine phosphonate analogue 43.7 and B) thioeth...
Figure 44: Enantioselective synthesis of phosphonates 44.3 and 44.4 [171].
Figure 45: Racemic synthesis of phosphinate-based ether lipid 45.10 [172].
Figure 46: Racemic synthesis of edelfosine arsonium analogue 46.5 [173].
Figure 47: Synthesis of edelfosine dimethylammonium analogue 47.2 [118].
Figure 48: Synthesis of rac-C18-edelfosine methylammonium analogue 48.4 [176].
Figure 49: A) Synthesis of edelfosine N-methylpyrrolidinium analogue 49.2 or N-methylmorpholinium analogue 49.3...
Figure 50: A) Synthesis of edelfosine’s analogue 50.4 with a PE polar group; B) illustration of a pyridinium d...
Figure 51: A) Synthesis of 51.4 featuring a thiazolium cationic moiety; B) synthesis of thiazolium-based EL 51...
Figure 52: Synthesis of cationic ether lipids 52.3, 52.4 and 52.6 [135,183].
Figure 53: Synthesis of cationic carbamate ether lipid 53.5 [184].
Figure 54: Synthesis of cationic sulfonamide 54.5 [185].
Figure 55: Chemical structure of ONO-6240 (55.1) and SRI-63-119 (55.2).
Figure 56: Synthesis of non-ionic ether lipids 56.2–56.9 [188].
Figure 57: Synthesis of ether lipid conjugated to foscarnet 57.6 [189].
Figure 58: A) Synthesis of ether lipid conjugated to arabinofuranosylcytosine; B) synthesis of AZT conjugated ...
Figure 59: Synthesis of quercetin conjugate to edelfosine [191].
Figure 60: Synthesis of 60.8 (Glc-PAF) [194].
Figure 61: A) Synthesis of amino ether lipid 61.7 functionalized with a rhamnose unit and its amide analogue 6...
Figure 62: A) Synthesis of glucose ether lipid 62.4; B) structure of ether lipid 62.5 possessing a maltose uni...
Figure 63: A) Synthesis of glucuronic methyl ester 63.8; B) structure of cellobiose 63.9 and maltose 63.10 ana...
Figure 64: A) Synthesis of maltosyl glycerolipid 64.7; B) structure of lactose analogue 64.8 prepared followin...
Figure 65: A) Asymmetric synthesis of the aglycone moiety starting from allyl 4-methoxyphenyl ether; B) glycos...
Figure 66: A) Synthesis of ohmline possessing a lactose moiety. B) Structure of other glyco glycero lipids pre...
Figure 67: A) Synthesis of lactose-glycerol ether lipid 67.5; B) analogues possessing a maltose (67.6) or meli...
Figure 68: Synthesis of digalactosyl EL 68.6, A) by using trityl, benzyl and acetyl protecting groups, B) by u...
Figure 69: A) Synthesis of α-ohmline; B) structure of disaccharide ether lipids prepared by using similar meth...
Figure 70: Synthesis of lactose ether lipid 70.3 and its analogue 70.6 featuring a carbamate function as linke...
Figure 71: Synthesis of rhamnopyranoside diether 71.4 [196].
Figure 72: Synthesis of 1-O-hexadecyl-2-O-methyl-3-S-(α-ᴅ-1'-thioglucopyranosyl)-sn-glycerol (72.5) [225].
Figure 73: A) Preparation of lipid intermediate 73.4; B) synthesis of 2-desoxy-C-glycoside 73.10 [226].
Figure 74: Synthesis of galactose-pyridinium salt 74.3 [228].
Figure 75: Synthesis of myo-inositol derivative Ino-C2-PAF (75.10) [230].
Figure 76: A) Synthesis of myo-inositol phosphate building block 76.7; B) synthesis of myo-inositolphosphate d...
Figure 77: A) Synthesis of phosphatidyl-3-desoxy-inositol 77.4; B) synthesis of phosphono-3-desoxyinositol 77.9...
Figure 78: A) Structure of diether phosphatidyl-myo-inositol-3,4-diphosphate 78.1; B) synthesis of phosphatidy...
Figure 79: A) Synthesis of diether-phosphatidyl derivative 79.4 featuring a hydroxymethyl group in place of a ...
Figure 80: Synthesis of Glc-amine-PAF [78].
Figure 81: Synthesis of glucosamine ether lipid 81.4 and its analogues functionalized in position 3 of the ami...
Figure 82: Synthesis of fully deprotected aminoglucoside ether lipid 82.5 [246].
Figure 83: Synthesis of C-aminoglycoside 83.12 using Ramberg–Bäcklund rearrangement as a key step [250].
Figure 84: A) List of the most important glyco lipids and amino glyco lipids included in the study of Arthur a...
Figure 85: Synthesis of mannosamine ether lipid 85.6 [254].
Figure 86: A) Synthesis of glucosamine ether lipids with a non-natural ʟ-glucosamine moiety; B) synthesis of e...
Figure 87: A) Structure of the most efficient anticancer agents 87.1–87.4 featuring a diamino glyco ether lipi...
Figure 88: A) Synthesis of diamino glyco ether lipid 87.4; B) synthesis of bis-glycosylated ether lipid 88.10 [256]....
Figure 89: Synthesis of triamino ether lipid 89.4 [260].
Figure 90: Synthesis of chlorambucil conjugate 90.7 [261].
Figure 91: Three main methods for the preparation of glycerol ether lipid 91.3; A) from solketal and via a tri...
Figure 92: Four different methods for the installation of the phosphocholine polar head group; A) method using...
Figure 93: Illustration of two methods for the installation of saccharides or aminosaccharides; A) O-glycosyla...
Synthesis of imidazo[4,5-e][1,3]thiazino[2,3-c][1,2,4]triazines via a base-induced rearrangement of functionalized imidazo[4,5-e]thiazolo[2,3-c][1,2,4]triazines
- Dmitry B. Vinogradov,
- Alexei N. Izmest’ev,
- Angelina N. Kravchenko,
- Yuri A. Strelenko and
- Galina A. Gazieva
Beilstein J. Org. Chem. 2023, 19, 1047–1054, doi:10.3762/bjoc.19.80
- [16][17]. Recent studies of the antitumor activity of imidazo[4,5-e]thiazolo[2,3-c]-1,2,4-triazines revealed a number of compounds with a high antiproliferative effect towards a large number of human cancer cell lines (Figure 1) [18][19]. Therefore, the synthesis of new imidazothiazolotriazines and
Graphical Abstract
Figure 1: Examples of natural and synthetic bioactive 1,3-thiazine and imidazothiazolotriazine derivatives wi...
Scheme 1: Base-induced transformations and rearrangements of functionalized imidazo[4,5-e]thiazolo[3,2-b]-1,2...
Scheme 2: Alkaline hydrolysis of esters 1a,b. aDetermined by 1H NMR spectroscopy; bisolated yields.
Scheme 3: Synthesis of potassium imidazo[4,5-e][1,3]thiazino[2,3-c][1,2,4]triazine-7-carboxylates.
Scheme 4: Plausible rearrangement mechanism of imidazo[4,5-e]thiazolo[2,3-c][1,2,4]triazine 1d into imidazo[4...
Figure 2: 1H NMR spectra of the starting compound 1d (a) and the reaction mixture after 1.5 (b) and 4 (c) hou...
Scheme 5: Synthetic approaches to imidazo[4,5-e][1,3]thiazino[2,3-c][1,2,4]triazines 3a–d,j.
Scheme 6: Synthesis of imidazo[4,5-e][1,3]thiazino[2,3-c][1,2,4]triazine-7-carboxylic acids 5a–j.
Scheme 7: Synthesis of imidazo[4,5-e][1,3]thiazino[2,3-c][1,2,4]triazine-7-carboxylic acids 5k,m.
Scheme 8: Plausible path for the formation of products 9.
Figure 3: 1H NMR spectra of compounds 4a and 5a in DMSO-d6 in the region of 4.3–9.0 ppm.
Figure 4: 13C NMR GATED spectra of compounds 4a and 5a in DMSO-d6 in the region of 156.0–168.0 ppm.
Figure 5: General view of 5a in the crystal in thermal ellipsoid representation (p = 80%).
Non-peptide compounds from Kronopolites svenhedini (Verhoeff) and their antitumor and iNOS inhibitory activities
- Yuan-Nan Yuan,
- Jin-Qiang Li,
- Hong-Bin Fang,
- Shao-Jun Xing,
- Yong-Ming Yan and
- Yong-Xian Cheng
Beilstein J. Org. Chem. 2023, 19, 789–799, doi:10.3762/bjoc.19.59
- compounds, cytotoxic and anti-inflammatory properties were evaluated. In particular, a mouse pancreatic cancer cell line (Panc02-h7-GP-GFP) was used to determine cytotoxicity. Additionally, LPS-induced pro-inflammatory expression of iNOS and COX-2 in RAW264.7 cells was evaluated. Antitumor activity of
- (TECAN, Switzerland). Antitumor activity assay of CD8+ T cells in vitro This assay, along with the associated experimental procedures, received approval from the Institutional Animal Care and Use Committee of Shenzhen University Health Science Center and the Animal Experimentation Ethics Committee of
- antitumor activity assay of CD8+ T cells in vitro. Funding This study was supported financially by the Shenzhen Science and Technology Program (No. KQTD20210811090219022), the Shenzhen Fundamental Research Program (No. JCYJ20200109114225087, JCYJ20210324120213038), and the National Science Fund for
Graphical Abstract
Figure 1: Structures of compounds 1–9.
Figure 2: Key 1H–1H COSY, HMBC, and ROESY correlations of compounds 1–4, 7, and 8.
Figure 3: Calculated and experimental ECD spectra of compounds 1 and 4.
Figure 4: Biological evaluation. Compounds 3‒5 inhibited the expression of LPS-induced pro-inflammatory expre...
Synthetic strategies for the preparation of γ-phostams: 1,2-azaphospholidine 2-oxides and 1,2-azaphospholine 2-oxides
- Jiaxi Xu
Beilstein J. Org. Chem. 2022, 18, 889–915, doi:10.3762/bjoc.18.90
- to the cyano group followed by hydrolysis to give the final product 223 (Scheme 36). The product 223 showed antitumor activity in a biological assay [20]. To develop antioxidants and antitumor agents, the same group synthesized chromene-fused 5-oxo-1,2-azaphospholidine 2-oxide derivatives. The
Graphical Abstract
Figure 1: Biologically active 1,2-azaphospholine 2-oxide derivatives.
Figure 2: Diverse synthetic strategies for the preparation of 1,2-azaphospholidine and 1,2-azaphospholine 2-o...
Scheme 1: Synthesis of 1-phenyl-2-phenylamino-γ-phosphonolactam (2) from N,N’-diphenyl 3-chloropropylphosphon...
Scheme 2: Synthesis of 2-ethoxy-1-methyl-γ-phosphonolactam (6) from ethyl N-methyl-(3-bromopropyl)phosphonami...
Scheme 3: Synthesis of 2-aryl-1-methyl-2,3-dihydrobenzo[c][1,2]azaphosphole 1-oxides 13 from N-aryl-2-chlorom...
Scheme 4: Synthesis of 2,3-dihydrobenzo[c][1,2]azaphosphole 1-oxides from alkylarylphosphinyl or diarylphosph...
Scheme 5: Synthesis of 3-arylmethylidene-2,3-dihydrobenzo[c][1,2]azaphosphole 1-oxides via the TBAF-mediated ...
Scheme 6: Synthesis of 2-hydrobenzo[c][1,2]azaphosphol-3-one 1-oxides via the metal-free intramolecular oxida...
Scheme 7: Synthesis of 1,3-dihydrobenzo[d][1,2]azaphosphole 2-oxides 42 and 44 from ethyl/benzyl 2-bromobenzy...
Scheme 8: Synthesis of azaphospholidine 2-oxides/sulfide from 1,2-oxaphospholane 2-oxides/sulfides and 1,2-th...
Scheme 9: Synthesis of 1,3-dihydrobenzo[d][1,2]azaphosphole 2-oxides/sulfides from 2-aminobenzyl(phenyl)phosp...
Scheme 10: Synthesis of 1,3-dihydrobenzo[d][1,2]azaphosphole 2-sulfide (59) from zwitterionic 2-aminobenzyl(ph...
Scheme 11: Synthesis of 1,3-dihydrobenzo[d][1,2]azaphosphole 2-oxides from 2-aminobenzyl(methyl/phenyl)phosphi...
Scheme 12: Synthesis of ethyl 2-methyl-1,2-azaphospholidine-5-carboxylate 2-oxide 69 from 2-amino-4-(hydroxy(m...
Scheme 13: Synthesis of 2-methoxy-1,3-dihydrobenzo[d][1,2]azaphosphole 2-oxide 71 from dimethyl 2-(methylamino...
Scheme 14: Synthesis of tricyclic γ-phosphonolactams via formation of the P–C bond.
Scheme 15: Synthesis of γ-phosphonolactams 85 from ethyl 2-(3-chloropropyl)aminoalkanoates with diethyl chloro...
Scheme 16: Synthesis of N-phosphoryl- and N-thiophosphoryl-1,2-azaphospholidine 2-oxides 90/2-sulfides 91 from...
Scheme 17: Synthesis of 1-methyl-1,3-dihydrobenzo[d][1,2]azaphosphole 2-oxides 56a and 93 from P-(chloromethyl...
Scheme 18: Synthesis of 2-allylamino-1,5-dihydro-1,2-azaphosphole 2-oxides from N,N’-diallyl-vinylphosphonodia...
Scheme 19: Diastereoselective synthesis of 2-allylamino-1,5-dihydro-1,2-azaphosphole 2-oxides from N,N’-dially...
Scheme 20: Synthesis of 1-alkyl-3-benzoyl-2-ethoxy-1,3-dihydrobenzo[d][1,2]azaphosphole 2-oxides 106 from ethy...
Scheme 21: Synthesis of cyclohexadiene-fused γ-phosphinolactams from diphenyl-N-benzyl-N-methylphosphinamide (...
Scheme 22: Synthesis of cyclohexadiene-fused γ-phosphinolactams from diphenyl-N-alkyl-N-benzylphosphinamides.
Scheme 23: Synthesis of cyclohexadiene-fused γ-phosphinolactams from diphenyl-N-methyl-N-(1-phenylethyl)phosph...
Scheme 24: Synthesis of benzocyclohexadiene-fused γ-phosphinolactams from dinaphth-1-yl-N-alkyl-N-benzylphosph...
Scheme 25: Synthesis of benzocyclohexadiene-fused γ-phosphinolactams from dinaphth-1-yl-N-benzyl-N-methylphosp...
Scheme 26: Synthesis of carbonyl-containing benzocyclohexadiene-fused γ-phosphinolactams from dinaphth-1-yl-N-...
Scheme 27: Synthesis of benzocyclohexadiene-fused γ-phosphinolactams from dinaphthyl-N-benzyl-N-methylphosphin...
Scheme 28: Synthesis of cyclohexadiene-fused 1-(N-benzyl-N-methyl)amino-γ-phosphinolactams from aryl-N,N’-dibe...
Scheme 29: Synthesis of bis(cyclohexadiene-fused γ-phosphinolactam)s from bis(diphenyl-N-benzylphosphinamide)s....
Scheme 30: Synthesis of bis(hydroxymethyl-derived cyclohexadiene-fused γ-phosphinolactam)s from tetramethylene...
Scheme 31: Synthesis of 2-aryl/dimethylamino-1-ethoxy-2-hydrobenzo[c][1,2]azaphosphol-3-one 1-oxides from ethy...
Scheme 32: Synthesis of ethyl 2-ethoxy-1,2-azaphospholidine-4-carboxylate 2-oxides from ethyl 2-((chloro(ethox...
Scheme 33: Synthesis of (1S,3R)-2-(tert-butyldiphenylsilyl)-3-methyl-1-phenyl-2,3-dihydrobenzo[c][1,2]azaphosp...
Scheme 34: Synthesis of 2,3,3a,9a-tetrahydro-4H-1,2-azaphospholo[5,4-b]chromen-4-one (215) from 3-(phenylamino...
Scheme 35: Synthesis of quinoline-fused 1,2-azaphospholine 2-oxides from 2-azidoquinoline-3-carbaldehydes and ...
Scheme 36: Synthesis of 1-hydro-1,2-azaphosphol-5-one 2-oxide from cyanoacetohydrazide with phosphonic acid an...
Scheme 37: Synthesis of chromene-fused 5-oxo-1,2-azaphospolidine 2-oxides.
Scheme 38: Synthesis of (R)-1-phenyl-2-((R)-1-phenylethyl)-2-hydrobenzo[c][1,2]azaphosphol-3-one 1-oxide (239)...
Scheme 39: Synthesis of dihydro[1,2]azaphosphole 1-oxides from aryl/vinyl-N-phenylphosphonamidates and aryl-N-...
Scheme 40: Synthesis of 1,3-dihydro-[1,2]azaphospholo[5,4-b]pyridine 2-oxides.
Copper-catalyzed multicomponent reactions for the efficient synthesis of diverse spirotetrahydrocarbazoles
- Shao-Cong Zhan,
- Ren-Jie Fang,
- Jing Sun and
- Chao-Guo Yan
Beilstein J. Org. Chem. 2022, 18, 796–808, doi:10.3762/bjoc.18.80
- Tetrahydrocarbazole is one of the most privileged heterocyclic core structures. It widely exists in various naturally occurring alkaloids and pharmacologically active compounds exhibiting important bioactivities such as antitumor activity and antiprotein kinase C activity [1][2][3]. Additionally, the corresponding
Graphical Abstract
Scheme 1: Construction of diverse tetrahydrocarbazoles via Levy-type reaction.
Scheme 2: Synthesis of spiro[carbazole-3,3'-inolines]. Reaction conditions: 2-methylindole (0.5 mmol), aromat...
Scheme 3: Synthesis of spiro[carbazole-2,3'-indolines]. Reaction conditions: 2-methylindole (0.5 mmol), aroma...
Scheme 4: Synthesis of tetrahydrospiro[carbazole-3,5'-pyrimidines]. Reaction conditions: 2-methylindole (0.5 ...
Scheme 5: Synthesis of tetrahydrospiro[carbazole-3,1'-cycloalkane]-diones. Reaction conditions: 2-methylindol...
Scheme 6: Synthesis of 3,3'-(arylmethylene)bis(2-methyl-1H-indole). Reaction conditions: 2-methylindole (1.0 ...
Scheme 7: Proposed reaction mechanism for the multicomponent reaction.
Synthesis of novel [1,2,4]triazolo[1,5-b][1,2,4,5]tetrazines and investigation of their fungistatic activity
- Anna V. Korotina,
- Svetlana G. Tolshchina,
- Rashida I. Ishmetova,
- Natalya P. Evstigneeva,
- Natalya A. Gerasimova,
- Natalya V. Zilberberg,
- Nikolay V. Kungurov,
- Gennady L. Rusinov,
- Oleg N. Chupakhin and
- Valery N. Charushin
Beilstein J. Org. Chem. 2022, 18, 243–250, doi:10.3762/bjoc.18.29
- -b][1,2,4,5]tetrazines [10], fungistatic activity of imidazo[1,2-b][1,2,4,5]tetrazines [11], antibacterial and antiglycation activity of imidazo[1,2-b]- and [1,2,4]triazolo[4,3-b][1,2,4,5]tetrazines [12][13][14] as well as antitumor activity of [1,2,4]triazolo[4,3-b][1,2,4,5]tetrazines [15][16] and
Graphical Abstract
Scheme 1: Chemical structures of [1,2,4]triazolo[4,3-b][1,2,4,5]tetrazine (a), [1,2,4]triazolo[1,5-b][1,2,4,5...
Scheme 2: Synthesis of [1,2,4]triazolo[1,5-b][1,2,4,5]tetrazines 3a–k.
Figure 1: X-ray structure of N-(6-(4-bromo-3,5-dimethylpyrazol-1-yl)-1,2,4,5-tetrazin-3-yl)benzamide.
Scheme 3: Reactions of triazolo[1,5-b][1,2,4,5]tetrazines 3a,j with N- and O-nucleophiles.
Scheme 4: Reactions of triazolo[1,5-b][1,2,4,5]tetrazines 3a,j with C-nucleophiles.
Scheme 5: Reactions of 6-(3,5-dimethyl-1H-pyrazol-1-yl)-3-methyl-[1,2,4]triazolo[4,3-b][1,2,4,5]tetrazine (10a...
1,2-Naphthoquinone-4-sulfonic acid salts in organic synthesis
- Ruan Carlos B. Ribeiro,
- Patricia G. Ferreira,
- Amanda de A. Borges,
- Luana da S. M. Forezi,
- Fernando de Carvalho da Silva and
- Vitor F. Ferreira
Beilstein J. Org. Chem. 2022, 18, 53–69, doi:10.3762/bjoc.18.5
- with antibacterial, fungicidal, antimalarial, antiviral, trypanocidal, leishmanicidal, and antitumor activity serve as inspiration for the pharmaceutical industry [21][22][23][24]. However, they are considered as Pan Assay Interference compounds (PAINS) because they display biological activity in many
- synthesis of novel 4-amino-1,2-naphthoquinones 43a–c containing carbohydrates and evaluated their antitumor activity in vitro. These compounds were transformed into a series of hydrazones 44a–l with different substituted aryl groups, which were also evaluated against tumor cells. To prepare 43a–c, 18 was
Graphical Abstract
Figure 1: Naphthoquinones are commonly used in organic synthesis.
Figure 2: Some important natural and synthetic naphthoquinones.
Scheme 1: Synthetic studies of BNQs and reactions with amines.
Scheme 2: Methods described for the synthesis of β-NQS.
Figure 3: Drugs detected using β-NQSNa.
Scheme 3: Reactions between β-NQS and amines.
Scheme 4: Isomerization of 4-arylamino-1,2-naphthoquinones.
Scheme 5: Synthesis of unsymmetrical 2-amino-4-imino compounds.
Scheme 6: Synthesis of bis(isoxazolyl)naphthoquinones from β-NQS.
Scheme 7: The reaction of β-NQS with 30 followed by cycle condensation.
Scheme 8: Synthesis of 4-(2-amino-5-selenothiazoles)-1,2-naphthoquinones.
Scheme 9: Synthesis of amino- and phenoxy-1,2-naphthoquinones.
Scheme 10: Synthesis of 4-semicarbazide-1,2-naphthoquinone.
Scheme 11: Reactions of 4-azido-1,2-naphthoquinone.
Figure 4: Modifications that can be easily carried out from the products of β-NQS 8.
Scheme 12: Derivatives of 1,2-naphthoquinones obtained from β-NQS.
Scheme 13: Oximes as well as 4-amino- and 4-phenoxy-1,2-naphthoquinone as potential anti-inflammatory agents.
Scheme 14: Synthesis of triazoles from β-NQS.
Scheme 15: Synthesis of naphtho[1,2-d]oxazoles from β-NQS.
Scheme 16: A) Arylation and vinylation of β-NQS catalyzed by Ni(II) salts. B) Transformation of the 1,2-dicarb...
Scheme 17: Benzo[a]carbazole and benzo[c]carbazoles fused with 1,2-naphthoquinone.
Scheme 18: Synthesis of 1,2-naphthoquinones having a C=C bond from β-NQS. Method A: NaOH, EtOH/H2O, 40 °C, 2 h...
Scheme 19: C=C bond formation from β-NQS and substituted acetonitriles.
Me3Al-mediated domino nucleophilic addition/intramolecular cyclisation of 2-(2-oxo-2-phenylethyl)benzonitriles with amines; a convenient approach for the synthesis of substituted 1-aminoisoquinolines
- Krishna M. S. Adusumalli,
- Lakshmi N. S. Konidena,
- Hima B. Gandham,
- Krishnaiah Kumari,
- Krishna R. Valluru,
- Satya K. R. Nidasanametla,
- Venkateswara R. Battula and
- Hari K. Namballa
Beilstein J. Org. Chem. 2021, 17, 2765–2772, doi:10.3762/bjoc.17.186
- applications in medicinal chemistry such as antimalarial, anti-Parkinson and antitumor activity (Figure 1) [13][14][15][16][17]. They also display remarkable enzymatic inhibitory activities on topoisomerase I, [18] mutant B-Raf [19] and exhibit antagonistic activities towards adenosine A3 [20] and PDE4B [21
Graphical Abstract
Figure 1: Biologically active 1-aminoisoquinolines.
Scheme 1: Comparison of our work with the previous approaches for the synthesis of 1-aminoisoquinolines.
Scheme 2: Substrate scope of anilines for the synthesis of 1-aminoisoquinolines (5a–m). Reaction conditions: 3...
Scheme 3: Substrate scope of 2-(2-oxo-2-phenylethyl)benzonitrile (3b–e) for the synthesis of 1-aminoisoquinol...
Scheme 4: Substrate scope of aliphatic amines for the synthesis of 1-aminoisoquinolines (5v–x), gram-scale sy...
Scheme 5: Proposed mechanism for the synthesis of 1-aminoisoquinoline 5a.
The ethoxycarbonyl group as both activating and protective group in N-acyl-Pictet–Spengler reactions using methoxystyrenes. A short approach to racemic 1-benzyltetrahydroisoquinoline alkaloids
- Marco Keller,
- Karl Sauvageot-Witzku,
- Franz Geisslinger,
- Nicole Urban,
- Michael Schaefer,
- Karin Bartel and
- Franz Bracher
Beilstein J. Org. Chem. 2021, 17, 2716–2725, doi:10.3762/bjoc.17.183
- ), and identified 1-benzyl-1,2,3,4-tetrahydroisoquinolines bearing phenoxy and benzyloxy substituents (SG-005, SG-094; for structures of bioactive compounds mentioned in this text, see Figure S1 in Supporting Information File 1) on both aromatic rings as potent blockers with promising antitumor activity
Graphical Abstract
Figure 1: Prominent synthetic approaches to 1-benzyltetrahydroisoquinolines: Bischler–Napieralski, Pictet–Spe...
Figure 2: Structures of N-methylcoclaurine (1) and the ten 1-benzyl-1,2,3,4-tetrahydroisoquinoline alkaloids ...
Figure 3: Two routes using N- and O-alkoxycarbonylated building blocks for the synthesis of phenolic N-methyl...
Figure 4: Structures of the building blocks A1–A4 (N-ethoxycarbonyl phenethylamines) and B1–B3 (ω-methoxystyr...
Figure 5: Biological activity. Antiproliferative effects of the 1-benzyltetrahydroisoquinoline alkaloids in A...
Strategies for the synthesis of brevipolides
- Yudhi D. Kurniawan and
- A'liyatur Rosyidah
Beilstein J. Org. Chem. 2021, 17, 2399–2416, doi:10.3762/bjoc.17.157
- scavenging [2]. Interestingly, the extracts also exhibited promising DNA intercalating agents [9] and antitumor activity [2]. The latter became more obvious when the chemical constituents of Hyptis brevipes Poit., the brevipolides A–F (1–6), were isolated for the first time by Kinghorn and co-workers in 2009
Graphical Abstract
Figure 1: Structures of brevipolides A–O (1 – 15).
Scheme 1: Retrosynthetic analysis of brevipolide H (8) by Kumaraswamy.
Scheme 2: Attempt to synthesize brevipolide H (8) by Kumaraswamy. (R,R)-Noyori cat. = RuCl[N-(tosyl)-1,2-diph...
Scheme 3: Attempt to synthesize brevipolide H (8) by Kumaraswamy (continued).
Scheme 4: Retrosynthetic analysis of brevipolide H (8) by Hou.
Scheme 5: Synthesis ent-brevipolide H (ent-8) by Hou.
Scheme 6: Retrosynthetic analysis of brevipolide H (8) by Mohapatra.
Scheme 7: Attempt to synthesize brevipolide H (8) by Mohapatra.
Scheme 8: Attempt to synthesize brevipolide H (8) by Mohapatra (continued). (+)-(IPC)2-BCl = (+)-B-chloro-dii...
Scheme 9: Retrosynthetic analysis of brevipolide H (8) by Hou.
Scheme 10: Synthesis of brevipolide H (8) by Hou.
Scheme 11: Retrosynthetic analysis of brevipolide M (13) by Sabitha.
Scheme 12: Synthesis of brevipolide M (13) by Sabitha.
Scheme 13: Retrosynthetic analysis of brevipolides M (13) and N (14) by Sabitha.
Scheme 14: Synthesis of brevipolides M (13) and N (14) by Sabitha.
On the application of 3d metals for C–H activation toward bioactive compounds: The key step for the synthesis of silver bullets
- Renato L. Carvalho,
- Amanda S. de Miranda,
- Mateus P. Nunes,
- Roberto S. Gomes,
- Guilherme A. M. Jardim and
- Eufrânio N. da Silva Júnior
Beilstein J. Org. Chem. 2021, 17, 1849–1938, doi:10.3762/bjoc.17.126
Graphical Abstract
Scheme 1: Schematic overview of transition metals studied in C–H activation processes.
Scheme 2: (A) Known biological activities related to benzimidazole-based compounds; (B and C) an example of a...
Scheme 3: (A) Known biological activities related to quinoline-based compounds; (B and C) an example of a sca...
Scheme 4: (A) Known biological activities related to sulfur-containing compounds; (B and C) an example of a s...
Scheme 5: (A) Known biological activities related to aminoindane derivatives; (B and C) an example of a scand...
Scheme 6: (A) Known biological activities related to norbornane derivatives; (B and C) an example of a scandi...
Scheme 7: (A) Known biological activities related to aniline derivatives; (B and C) an example of a titanium-...
Scheme 8: (A) Known biological activities related to cyclohexylamine derivatives; (B) an example of an intram...
Scheme 9: (A) Known biologically active benzophenone derivatives; (B and C) photocatalytic oxidation of benzy...
Scheme 10: (A) Known bioactive fluorine-containing compounds; (B and C) vanadium-mediated C(sp3)–H fluorinatio...
Scheme 11: (A) Known biologically active Lythraceae alkaloids; (B) synthesis of (±)-decinine (30).
Scheme 12: (A) Synthesis of (R)- and (S)-boehmeriasin (31); (B) synthesis of phenanthroindolizidines by vanadi...
Scheme 13: (A) Known bioactive BINOL derivatives; (B and C) vanadium-mediated oxidative coupling of 2-naphthol...
Scheme 14: (A) Known antiplasmodial imidazopyridazines; (B) practical synthesis of 41.
Scheme 15: (A) Gold-catalyzed drug-release mechanism using 2-alkynylbenzamides; (B and C) chromium-mediated al...
Scheme 16: (A) Examples of anti-inflammatory benzaldehyde derivatives; (B and C) chromium-mediated difunctiona...
Scheme 17: (A and B) Manganese-catalyzed chemoselective intramolecular C(sp3)–H amination; (C) late-stage modi...
Scheme 18: (A and B) Manganese-catalyzed C(sp3)–H amination; (C) late-stage modification of a leelamine deriva...
Scheme 19: (A) Known bioactive compounds containing substituted N-heterocycles; (B and C) manganese-catalyzed ...
Scheme 20: (A) Known indoles that present GPR40 full agonist activity; (B and C) manganese-catalyzed C–H alkyl...
Scheme 21: (A) Examples of known biaryl-containing drugs; (B and C) manganese-catalyzed C–H arylation through ...
Scheme 22: (A) Known zidovudine derivatives with potent anti-HIV properties; (B and C) manganese-catalyzed C–H...
Scheme 23: (A and B) Manganese-catalyzed C–H organic photo-electrosynthesis; (C) late-stage modification.
Scheme 24: (A) Example of a known antibacterial silylated dendrimer; (B and C) manganese-catalyzed C–H silylat...
Scheme 25: (A and B) Fe-based small molecule catalyst applied for selective aliphatic C–H oxidations; (C) late...
Scheme 26: (A) Examples of naturally occurring gracilioethers; (B) the first total synthesis of gracilioether ...
Scheme 27: (A and B) Selective aliphatic C–H oxidation of amino acids; (C) late-stage modification of proline-...
Scheme 28: (A) Examples of Illicium sesquiterpenes; (B) first chemical synthesis of (+)-pseudoanisatin (80) in...
Scheme 29: (A and B) Fe-catalyzed deuteration; (C) late-stage modification of pharmaceuticals.
Scheme 30: (A and B) Biomimetic Fe-catalyzed aerobic oxidation of methylarenes to benzaldehydes (PMHS, polymet...
Scheme 31: (A) Known tetrahydroquinolines with potential biological activities; (B and C) redox-selective Fe c...
Scheme 32: (A) Known drugs containing a benzofuran unit; (B and C) Fe/Cu-catalyzed tandem O-arylation to acces...
Scheme 33: (A) Known azaindolines that act as M4 muscarinic acetylcholine receptor agonists; (B and C) intramo...
Scheme 34: (A) Known indolinones with anticholinesterase activity; (B and C) oxidative C(sp3)–H cross coupling...
Scheme 35: (A and B) Cobalt-catalyzed C–H alkenylation of C-3-peptide-containing indoles; (C) derivatization b...
Scheme 36: (A) Cobalt-Cp*-catalyzed C–H methylation of known drugs; (B and C) scope of the o-methylated deriva...
Scheme 37: (A) Known lasalocid A analogues; (B and C) three-component cobalt-catalyzed C–H bond addition; (D) ...
Scheme 38: (A and B) Cobalt-catalyzed C(sp2)–H amidation of thiostrepton.
Scheme 39: (A) Known 4H-benzo[d][1,3]oxazin-4-one derivatives with hypolipidemic activity; (B and C) cobalt-ca...
Scheme 40: (A and B) Cobalt-catalyzed C–H arylation of pyrrole derivatives; (C) application for the synthesis ...
Scheme 41: (A) Known 2-phenoxypyridine derivatives with potent herbicidal activity; (B and C) cobalt-catalyzed...
Scheme 42: (A) Natural cinnamic acid derivatives; (B and C) cobalt-catalyzed C–H carboxylation of terminal alk...
Scheme 43: (A and B) Cobalt-catalyzed C–H borylation; (C) application to the synthesis of flurbiprofen.
Scheme 44: (A) Benzothiazoles known to present anticonvulsant activities; (B and C) cobalt/ruthenium-catalyzed...
Scheme 45: (A and B) Cobalt-catalyzed oxygenation of methylene groups towards ketone synthesis; (C) synthesis ...
Scheme 46: (A) Known anticancer tetralone derivatives; (B and C) cobalt-catalyzed C–H difluoroalkylation of ar...
Scheme 47: (A and B) Cobalt-catalyzed C–H thiolation; (C) application in the synthesis of quetiapine (153).
Scheme 48: (A) Known benzoxazole derivatives with anticancer, antifungal, and antibacterial activities; (B and...
Scheme 49: (A and B) Cobalt-catalyzed C–H carbonylation of naphthylamides; (C) BET inhibitors 158 and 159 tota...
Scheme 50: (A) Known bioactive pyrrolo[1,2-a]quinoxalin-4(5H)-one derivatives; (B and C) cobalt-catalyzed C–H ...
Scheme 51: (A) Known antibacterial cyclic sulfonamides; (B and C) cobalt-catalyzed C–H amination of propargyli...
Scheme 52: (A and B) Cobalt-catalyzed intramolecular 1,5-C(sp3)–H amination; (C) late-stage functionalization ...
Scheme 53: (A and B) Cobalt-catalyzed C–H/C–H cross-coupling between benzamides and oximes; (C) late-state syn...
Scheme 54: (A) Known anticancer natural isoquinoline derivatives; (B and C) cobalt-catalyzed C(sp2)–H annulati...
Scheme 55: (A) Enantioselective intramolecular nickel-catalyzed C–H activation; (B) bioactive obtained motifs;...
Scheme 56: (A and B) Nickel-catalyzed α-C(sp3)–H arylation of ketones; (C) application of the method using kno...
Scheme 57: (A and B) Nickel-catalyzed C(sp3)–H acylation of pyrrolidine derivatives; (C) exploring the use of ...
Scheme 58: (A) Nickel-catalyzed C(sp3)–H arylation of dioxolane; (B) library of products obtained from biologi...
Scheme 59: (A) Intramolecular enantioselective nickel-catalyzed C–H cycloalkylation; (B) product examples, inc...
Scheme 60: (A and B) Nickel-catalyzed C–H deoxy-arylation of azole derivatives; (C) late-stage functionalizati...
Scheme 61: (A and B) Nickel-catalyzed decarbonylative C–H arylation of azole derivatives; (C) application of t...
Scheme 62: (A and B) Another important example of nickel-catalyzed C–H arylation of azole derivatives; (C) app...
Scheme 63: (A and B) Another notable example of a nickel-catalyzed C–H arylation of azole derivatives; (C) lat...
Scheme 64: (A and B) Nickel-based metalorganic framework (MOF-74-Ni)-catalyzed C–H arylation of azole derivati...
Scheme 65: (A) Known commercially available benzothiophene-based drugs; (B and C) nickel-catalyzed C–H arylati...
Scheme 66: (A) Known natural tetrahydrofuran-containing substances; (B and C) nickel-catalyzed photoredox C(sp3...
Scheme 67: (A and B) Another notable example of a nickel-catalyzed photoredox C(sp3)–H alkylation/arylation; (...
Scheme 68: (A) Electrochemical/nickel-catalyzed C–H alkoxylation; (B) achieved scope, including three using na...
Scheme 69: (A) Enantioselective photoredox/nickel catalyzed C(sp3)–H arylation; (B) achieved scope, including ...
Scheme 70: (A) Known commercially available trifluoromethylated drugs; (B and C) nickel-catalyzed C–H trifluor...
Scheme 71: (A and B) Stereoselective nickel-catalyzed C–H difluoroalkylation; (C) late-stage functionalization...
Scheme 72: (A) Cu-mediated ortho-amination of oxalamides; (B) achieved scope, including derivatives obtained f...
Scheme 73: (A) Electro-oxidative copper-mediated amination of 8-aminoquinoline-derived amides; (B) achieved sc...
Scheme 74: (A and B) Cu(I)-mediated C–H amination with oximes; (C) derivatization using telmisartan (241) as s...
Scheme 75: (A and B) Cu-mediated amination of aryl amides using ammonia; (C) late-stage modification of proben...
Scheme 76: (A and B) Synthesis of purine nucleoside analogues using copper-mediated C(sp2)–H activation.
Scheme 77: (A) Copper-mediated annulation of acrylamide; (B) achieved scope, including the synthesis of the co...
Scheme 78: (A) Known bioactive compounds containing a naphthyl aryl ether motif; (B and C) copper-mediated eth...
Scheme 79: (A and B) Cu-mediated alkylation of N-oxide-heteroarenes; (C) late-stage modification.
Scheme 80: (A) Cu-mediated cross-dehydrogenative coupling of polyfluoroarenes and alkanes; (B) scope from know...
Scheme 81: (A) Known anticancer acrylonitrile compounds; (B and C) Copper-mediated cyanation of unactivated al...
Scheme 82: (A) Cu-mediated radiofluorination of 8-aminoquinoline-derived aryl amides; (B) achieved scope, incl...
Scheme 83: (A) Examples of natural β-carbolines; (B and C) an example of a zinc-catalyzed C–H functionalizatio...
Scheme 84: (A) Examples of anticancer α-aminophosphonic acid derivatives; (B and C) an example of a zinc-catal...
A recent overview on the synthesis of 1,4,5-trisubstituted 1,2,3-triazoles
- Pezhman Shiri,
- Ali Mohammad Amani and
- Thomas Mayer-Gall
Beilstein J. Org. Chem. 2021, 17, 1600–1628, doi:10.3762/bjoc.17.114
- to afford 5-stibanotriazoles 93 in good yield (Scheme 27) [54]. The 5-stibanotriazoles 93 were used as intermediates for the synthesis of 5-unsubstituted triazoles 94 in the presence of HCl (10%) in THF at 0 °C. The antitumor activity of 5-stibanotriazoles 93 as well as 5-unsubstituted triazoles 94
- was explored using some tumor cell lines. The results exhibited that 5-stibanotriazoles 93 exerted a superior antitumor activity. Contrariwise, 5-unsubstituted 1,2,3-triazoles showed very low antitumor activity in comparison to 5-stibanotriazoles. Since 5-unsubstituted 1,2,3-triazoles did not display
- good antitumor activity in comparison to 5-stibanotriazoles, this reinforces the importance of synthesizing 5-stibanotriazoles [54]. A similar reaction for the regioselective synthesis of triazole disulfides 98 through a copper(I)-catalyzed cycloaddition of azides 95, alkynes 96, and tert-butyl tosyl
Graphical Abstract
Figure 1: Some significant triazole derivatives [8,23-27].
Scheme 1: A general comparison between synthetic routes for disubstituted 1,2,3-triazole derivatives and full...
Scheme 2: Synthesis of formyltriazoles 3 from the treatment of α-bromoacroleins 1 with azides 2.
Scheme 3: A probable mechanism for the synthesis of formyltriazoles 5 from the treatment of α-bromoacroleins 1...
Scheme 4: Synthesis of 1,4,5-trisubstituted 1,2,3-triazoles 8 from the reaction of aryl azides 7 with enamino...
Scheme 5: Proposed mechanism for the synthesis of 1,4,5-trisubstituted 1,2,3-triazoles from the reaction of a...
Scheme 6: Synthesis of 1,4,5-trisubstituted 1,2,3-triazoles 11 from the reaction of primary amines 10 with 1,...
Scheme 7: The proposed mechanism for the synthesis of 1,4,5-trisubstituted 1,2,3-triazoles 11 from the reacti...
Scheme 8: Synthesis of fully decorated 1,2,3-triazoles 19 containing a sulfur-based side chain.
Scheme 9: Mechanism for the formation of fully decorated 1,2,3-triazoles 19 containing a sulfur-based side ch...
Scheme 10: Synthesis of fully decorated 1,2,3-triazole compounds 25 through the regioselective addition and cy...
Scheme 11: A reasonable mechanism for the synthesis of fully decorated 1,2,3-triazole compounds 25 through the...
Scheme 12: Synthesis of 1,4,5-trisubstituted glycosyl-containing 1,2,3-triazole derivatives 30 from the reacti...
Scheme 13: Synthesis of 1,4,5-trisubstituted 1,2,3-triazoles 34 via intramolecular cyclization reaction of ket...
Scheme 14: Synthesis of fully decorated 1,2,3-triazoles 38 from the reaction of aldehydes 35, amines 36, and α...
Scheme 15: A reasonable mechanism for the synthesis of fully decorated 1,2,3-triazoles 38 from the reaction of...
Scheme 16: Synthesis of functionally rich double C- and N-vinylated 1,2,3-triazoles 45 and 47.
Scheme 17: Synthesis of disubstituted 4-chloro-, 4-bromo-, and 4-iodo-1,2,3-triazoles 50.
Scheme 18: a) A general route for SPAAC in polymer chemistry and b) synthesis of a novel pH-sensitive polymeri...
Scheme 19: Synthesis of 5-allenyl-1,2,3-triazoles 60 by the treatment of alkynes 57, azides 58, and propargyli...
Scheme 20: A reasonable mechanism for the synthesis of 5-allenyl-1,2,3-triazoles 60 by the treatment of alkyne...
Scheme 21: Synthesis of 5‐alkynyl-1,2,3-triazoles 69.
Scheme 22: A reasonable mechanism for the synthesis of 5‐alkynyl-1,2,3-triazoles 69.
Scheme 23: Synthesis of sulfur-cycle-fused 1,2,3-triazoles 75 and 77.
Scheme 24: A reasonable mechanism for the synthesis of sulfur-cycle-fused 1,2,3‐triazoles 75 and 77.
Scheme 25: Synthesis of 5-selanyltriazoles 85 from the reaction of ethynylstibanes 82, organic azides 83, and ...
Scheme 26: A mechanism for the synthesis of 5-selanyltriazoles 85 from the reaction of ethynylstibanes 82, org...
Scheme 27: Synthesis of trisubstituted triazoles containing an Sb substituent at position C5 in 93 and 5-unsub...
Scheme 28: Synthesis of asymmetric triazole disulfides 98 from disulfide-containing tert-butyltosyl disulfide 97...
Scheme 29: A mechanism for the synthesis of asymmetric triazole disulfides 98 from disulfide-containing tert-bu...
Scheme 30: Synthesis of triazole-fused sultams 104.
Scheme 31: Synthesis of 1,2,3-triazole-fused tricyclic heterocycles 106.
Scheme 32: A reasonable mechanism for the synthesis of 1,2,3-triazole-fused tricyclic heterocycles 106.
Scheme 33: Synthesis of 5-aryl-substituted 1,2,3-triazole derivatives 112.
Scheme 34: A reasonable mechanism for the synthesis of 5-aryl-substituted 1,2,3-triazole derivatives 112.
Scheme 35: Synthesis of 1,4,5-trisubstituted 1,2,3-triazole-5-carboxamides 119.
Scheme 36: A probable mechanism for the synthesis of 1,4,5-trisubstituted 1,2,3-triazole-5-carboxamides 119.
Scheme 37: Synthesis of fully decorated triazoles 125 via the Pd/C-catalyzed arylation of disubstituted triazo...
Scheme 38: Synthesis of triazolo[1,5-a]indolones 131.
Scheme 39: Synthesis of unsymmetrically substituted triazole-fused enediyne systems 135 and 5-aryl-4-ethynyltr...
Scheme 40: Synthesis of Pd/Cu-BNP 139 and application of 139 in the synthesis of polycyclic triazoles 142.
Scheme 41: A probable mechanism for the synthesis of polycyclic triazoles 142.
Scheme 42: Synthesis of highly functionalized 1,2,3-triazole-fused 5-, 6-, and 7-membered rings 152–154.
Scheme 43: A probable mechanism for the synthesis of highly functionalized 1,2,3-triazole-fused 5-, 6-, and 7-...
Scheme 44: Synthesis of fully functionalized 1,2,3-triazolo-fused chromenes 162, 164, and 166 via the intramol...
Scheme 45: Ru-catalyzed synthesis of fully decorated triazoles 172.
Scheme 46: Synthesis of 4-cyano-1,2,3-triazoles 175.
Scheme 47: Synthesis of functionalized triazoles from the reaction of 1-alkyltriazenes 176 and azides 177 and ...
Scheme 48: Mechanism for the synthesis of functionalized triazoles from the reaction of 1-alkyltriazenes 176 a...
Beyond ribose and phosphate: Selected nucleic acid modifications for structure–function investigations and therapeutic applications
- Christopher Liczner,
- Kieran Duke,
- Gabrielle Juneau,
- Martin Egli and
- Christopher J. Wilds
Beilstein J. Org. Chem. 2021, 17, 908–931, doi:10.3762/bjoc.17.76
- overall steps [164]. ASOs containing these modified nucleosides have demonstrated promising antitumor activity for lymphoma and lung cancer [165]. Numerous other LNA analogues have been constructed including, but not limited to, 2'-N-guanidino,4'-C-ethylene (GENA) (Figure 7I) [166], sulfonamide-bridged
Graphical Abstract
Figure 1: Structures of the chemically modified oligonucleotides (A) N3' → P5' phosphoramidate linkage, (B) a...
Scheme 1: Synthesis of a N3' → P5' phosphoramidate linkage by solid-phase synthesis. (a) dichloroacetic acid;...
Figure 2: Crystal structures of (A) N3' → P5' phosphoramidate DNA (PDB ID 363D) [71] and (B) amide (AM1) RNA in c...
Scheme 2: Synthesis of a phosphorodithioate linkage by solid-phase synthesis. (a) detritylation; (b) tetrazol...
Figure 3: Close-up view of a key interaction between the PS2-modified antithrombin RNA aptamer and thrombin i...
Scheme 3: Synthesis of the (S)-GNA thymine phosphoramidite from (S)-glycidyl 4,4'-dimethoxytrityl ether. (a) ...
Figure 4: Surface models of the crystal structures of RNA dodecamers with single (A) (S)-GNA-T (PDB ID 5V1L) [54]...
Figure 5: Structures of 2'-O-alkyl modifications. (A) 2'-O-methoxy RNA (2'-OMe RNA), (B) 2'-O-(2-methoxyethyl...
Scheme 4: Synthesis of the 2'-OMe uridine from 3',5'-O-(tetraisopropyldisiloxane-1,3-diyl)uridine. (a) Benzoy...
Scheme 5: Synthesis of the 2'-O-MOE uridine from uridine. (a) (PhO)2CO, NaHCO3, DMA, 100 °C; (b) Al(OCH2CH2OCH...
Figure 6: Structure of 2'-O-(2-methoxyethyl)-RNA (MOE-RNA). (A) View into the minor groove of an A-form DNA d...
Figure 7: Structures of locked nucleic acids (LNA)/bridged nucleic acids (BNA) modifications. (A) LNA/BNA, (B...
Scheme 6: Synthesis of the uridine LNA phosphoramidite. (a) i) NaH, BnBr, DMF, ii) acetic anhydride, pyridine...
Scheme 7: Synthesis of the 2'-fluoroarabinothymidine. (a) 30% HBr in acetic acid; (b) 2,4-bis-O-(trimethylsil...
Figure 8: Sugar puckers of arabinose (ANA) and arabinofluoro (FANA) nucleic acids compared with the puckers o...
Figure 9: Structures of C4'-modified nucleic acids. (A) 4'-methoxy, (B) 4'-(2-methoxyethoxy), (C) 2',4'-diflu...
Scheme 8: Synthesis of the 4'-F-rU phosphoramidite. (a) AgF, I2, dichloromethane, tetrahydrofuran; (b) NH3, m...
Scheme 9: Synthesis of the thymine FHNA phosphoramidite. (a) thymine, 1,8-diazabicyclo[5.4.0]undec-7-ene, ace...
Scheme 10: Synthesis of the thymine Ara-FHNA phosphoramidite. (a) i) trifluoromethanesulfonic anhydride, pyrid...
Figure 10: Crystal structures of (A) FHNA and (B) Ara-FHNA in modified A-form DNA decamers (PDB IDs 3Q61 and 3...
Effective microwave-assisted approach to 1,2,3-triazolobenzodiazepinones via tandem Ugi reaction/catalyst-free intramolecular azide–alkyne cycloaddition
- Maryna O. Mazur,
- Oleksii S. Zhelavskyi,
- Eugene M. Zviagin,
- Svitlana V. Shishkina,
- Vladimir I. Musatov,
- Maksim A. Kolosov,
- Elena H. Shvets,
- Anna Yu. Andryushchenko and
- Valentyn A. Chebanov
Beilstein J. Org. Chem. 2021, 17, 678–687, doi:10.3762/bjoc.17.57
- high anticonvulsant activity after tests in silico and in vivо [7]. Moreover, compounds C and D reveal high activity as casein kinase 2 (CK2) inhibitor and high antitumor activity which makes compounds to be promising anticancer drugs [8]. There are quite a few methods for the synthesis of the
Graphical Abstract
Figure 1: Benzodiazepine-based azolo-containing drugs.
Figure 2: Novel potential 1,2,3-triazolobenziadiazepine drugs.
Scheme 1: Examples of synthesis of 1,2,3-triazolobenzodiazepines via tandem approach Ugi reaction/IAAC. Reage...
Scheme 2: Azide precursor synthesis.
Scheme 3: Synthesis of Ugi products 6, their structures and yields.
Figure 3: Code legend for Ugi products 6 and molecular structure (X-ray analysis) of compound 6aaa.
Scheme 4: Cyclization of Ugi-product 6aab with terminal alkyne fragment.
Figure 4: 1H NMR spectra of the reactant and the product of IAAC.
Figure 5: Molecular structure of compound 7aaa (X-ray analysis) and comparison of 1H NMR spectra of compounds ...
Scheme 5: The substrate scope of intermolecular cycloaddition.
The preparation and properties of 1,1-difluorocyclopropane derivatives
- Kymbat S. Adekenova,
- Peter B. Wyatt and
- Sergazy M. Adekenov
Beilstein J. Org. Chem. 2021, 17, 245–272, doi:10.3762/bjoc.17.25
Graphical Abstract
Scheme 1: Synthesis of 1,1-difluoro-2,3-dimethylcyclopropane (2).
Scheme 2: Cyclopropanation via dehydrohalogenation of chlorodifluoromethane.
Scheme 3: Difluorocyclopropanation of methylstyrene 7 using dibromodifluoromethane and zinc.
Scheme 4: Synthesis of difluorocyclopropanes from the reaction of dibromodifluoromethane and triphenylphosphi...
Scheme 5: Generation of difluorocarbene in a catalytic two-phase system and its addition to tetramethylethyle...
Scheme 6: The reaction of methylstyrene 7 with chlorodifluoromethane (11) in the presence of a tetraarylarson...
Scheme 7: Pyrolysis of sodium chlorodifluoroacetate (12) in refluxing diglyme in the presence of alkene 13.
Scheme 8: Synthesis of boron-substituted gem-difluorocyclopropanes 16.
Scheme 9: Addition of sodium bromodifluoroacetate (17) to alkenes.
Scheme 10: Addition of sodium bromodifluoroacetate (17) to silyloxy-substituted cyclopropanes 20.
Scheme 11: Synthesis of difluorinated nucleosides.
Scheme 12: Addition of butyl acrylate (26) to difluorocarbene generated from TFDA (25).
Scheme 13: Addition of difluorocarbene to propargyl esters 27 and conversion of the difluorocyclopropenes 28 t...
Scheme 14: The generation of difluorocyclopropanes using MDFA 30.
Scheme 15: gem-Difluorocyclopropanation of styrene (32) using difluorocarbene generated from TMSCF3 (31) under...
Scheme 16: Synthesis of a gem-difluorocyclopropane derivative using HFPO (41) as a source of difluorocarbene.
Scheme 17: Cyclopropanation of (Z)-2-butene in the presence of difluorodiazirine (44).
Scheme 18: The cyclopropanation of 1-octene (46) using Seyferth's reagent (45) as a source of difluorocarbene.
Scheme 19: Alternative approaches for the difluorocarbene synthesis from trimethyl(trifluoromethyl)tin (48).
Scheme 20: Difluorocyclopropanation of cyclohexene (49).
Scheme 21: Synthesis of difluorocyclopropane derivative 53 using bis(trifluoromethyl)cadmium (51) as the diflu...
Scheme 22: Addition of difluorocarbene generated from tris(trifluoromethyl)bismuth (54).
Scheme 23: Addition of a stable (trifluoromethyl)zinc reagent to styrenes.
Scheme 24: The preparation of 2,2-difluorocyclopropanecarboxylic acids of type 58.
Scheme 25: Difluorocyclopropanation via Michael cyclization.
Scheme 26: Difluorocyclopropanation using N-acylimidazolidinone 60.
Scheme 27: Difluorocyclopropanation through the cyclization of phenylacetonitrile (61) and 1,2-dibromo-1,1-dif...
Scheme 28: gem-Difluoroolefins 64 for the synthesis of functionalized cyclopropanes 65.
Scheme 29: Preparation of aminocyclopropanes 70.
Scheme 30: Synthesis of fluorinated methylenecyclopropane 74 via selenoxide elimination.
Scheme 31: Reductive dehalogenation of (1R,3R)-75.
Scheme 32: Synthesis of chiral monoacetates by lipase catalysis.
Scheme 33: Transformation of (±)-trans-81 using Rhodococcus sp. AJ270.
Scheme 34: Transformation of (±)-trans-83 using Rhodococcus sp. AJ270.
Scheme 35: Hydrogenation of difluorocyclopropenes through enantioselective hydrocupration.
Scheme 36: Enantioselective transfer hydrogenation of difluorocyclopropenes with a Ru-based catalyst.
Scheme 37: The thermal transformation of trans-1,2-dichloro-3,3-difluorocyclopropane (84).
Scheme 38: cis–trans-Epimerization of 1,1-difluoro-2,3-dimethylcyclopropane.
Scheme 39: 2,2-Difluorotrimethylene diradical intermediate.
Scheme 40: Ring opening of stereoisomers 88 and 89.
Scheme 41: [1,3]-Rearrangement of alkenylcyclopropanes 90–92.
Scheme 42: Thermolytic rearrangement of 2,2-difluoro-1-vinylcyclopropane (90).
Scheme 43: Thermal rearrangement for ethyl 3-(2,2-difluoro)-3-phenylcyclopropyl)acrylates 93 and 95.
Scheme 44: Possible pathways of the ring opening of 1,1-difluoro-2-vinylcyclopropane.
Scheme 45: Equilibrium between 1,1-difluoro-2-methylenecyclopropane (96) and (difluoromethylene)cyclopropane 97...
Scheme 46: Ring opening of substituted 1,1-difluoro-2,2-dimethyl-3-methylenecyclopropane 98.
Scheme 47: 1,1-Difluorospiropentane rearrangement.
Scheme 48: Acetolysis of (2,2-difluorocyclopropyl)methyl tosylate (104) and (1,1-difluoro-2-methylcyclopropyl)...
Scheme 49: Ring opening of gem-difluorocyclopropyl ketones 106 and 108 by thiolate nucleophiles.
Scheme 50: Hydrolysis of gem-difluorocyclopropyl acetals 110.
Scheme 51: Ring-opening reaction of 2,2-difluorocyclopropyl ketones 113 in the presence of ionic liquid as a s...
Scheme 52: Ring opening of gem-difluorocyclopropyl ketones 113a by MgI2-initiated reaction with diarylimines 1...
Scheme 53: Ring-opening reaction of gem-difluorocyclopropylstannanes 117.
Scheme 54: Preparation of 1-fluorovinyl vinyl ketone 123 and the synthesis of 2-fluorocyclopentenone 124. TBAT...
Scheme 55: Iodine atom-transfer ring opening of 1,1-difluoro-2-(1-iodoalkyl)cyclopropanes 125a–c.
Scheme 56: Ring opening of bromomethyl gem-difluorocyclopropanes 130 and formation of gem-difluoromethylene-co...
Scheme 57: Ring-opening aerobic oxidation reaction of gem-difluorocyclopropanes 132.
Scheme 58: Dibrominative ring-opening functionalization of gem-difluorocyclopropanes 134.
Scheme 59: The selective formation of (E,E)- and (E,Z)-fluorodienals 136 and 137 from difluorocyclopropyl acet...
Scheme 60: Proposed mechanism for the reaction of difluoro(methylene)cyclopropane 139 with Br2.
Scheme 61: Thermal rearrangement of F2MCP 139 and iodine by CuI catalysis.
Scheme 62: Synthesis of 2-fluoropyrroles 142.
Scheme 63: Ring opening of gem-difluorocyclopropyl ketones 143 mediated by BX3.
Scheme 64: Lewis acid-promoted ring-opening reaction of 2,2-difluorocyclopropanecarbonyl chloride (148).
Scheme 65: Ring-opening reaction of the gem-difluorocyclopropyl ketone 106 by methanolic KOH.
Scheme 66: Hydrogenolysis of 1,1-difluoro-3-methyl-2-phenylcyclopropane (151).
Scheme 67: Synthesis of monofluoroalkenes 157.
Scheme 68: The stereoselective Ag-catalyzed defluorinative ring-opening diarylation of 1-trimethylsiloxy-2,2-d...
Scheme 69: Synthesis of 2-fluorinated allylic compounds 162.
Scheme 70: Pd-catalyzed cross-coupling reactions of gem-difluorinated cyclopropanes 161.
Scheme 71: The (Z)-selective Pd-catalyzed ring-opening sulfonylation of 2-(2,2-difluorocyclopropyl)naphthalene...
Figure 1: Structures of zosuquidar hydrochloride and PF-06700841.
Scheme 72: Synthesis of methylene-gem-difluorocyclopropane analogs of nucleosides.
Figure 2: Anthracene-difluorocyclopropane hybrid derivatives.
Figure 3: Further examples of difluorcyclopropanes in modern drug discovery.
Synthesis of pyrrolidinedione-fused hexahydropyrrolo[2,1-a]isoquinolines via three-component [3 + 2] cycloaddition followed by one-pot N-allylation and intramolecular Heck reactions
- Xiaoming Ma,
- Suzhi Meng,
- Xiaofeng Zhang,
- Qiang Zhang,
- Shenghu Yan,
- Yue Zhang and
- Wei Zhang
Beilstein J. Org. Chem. 2020, 16, 1225–1233, doi:10.3762/bjoc.16.106
- crispine A isolated from Carduus crispus L has antitumor activity [3]. Erythrina alkaloids have curare-like neuromuscular blocking activities [4], and also antioxidant activity against DPPH free radicals [5]. Lamellarins isolated from marine invertebrates [6] are inhibitors for HIV-1 integrase and also
Graphical Abstract
Figure 1: Bioactive pyrrolo[2,1-a]isoquinolines and hexahydropyrrolo[2,1-a]isoquinolines.
Scheme 1: [3 + 2] Cycloaddition with amino esters or amino acids.
Scheme 2: Scaffolds derived from the initial [3 + 2] adducts.
Scheme 3: [3 + 2] Cycloaddition with amino esters or amino acids. Conditions: 1:3:4 (1.2:1:1.1), Et3N (1.5 eq...
Scheme 4: Synthesis of pyrrolo[2,1-a]isoquinolines 9. Reaction conditions: 5 (0.5 mmol, 1 equiv), 7 (3 equiv)...
Scheme 5: Synthesis of pyrrolo[2,1-a]isoquinolines 11. Reaction conditions: 6 (0.5 mmol, 1 equiv), 7 (3 equiv...
Scheme 6: Synthesis of pyrrolo[2,1-a]isoquinolines 12. Reaction conditions: 5 or 6 (0.5 mmol, 1 equiv), cinna...
Scheme 7: Plausible mechanism for the synthesis of 9a.
Synthesis and anticancer activity of bis(2-arylimidazo[1,2-a]pyridin-3-yl) selenides and diselenides: the copper-catalyzed tandem C–H selenation of 2-arylimidazo[1,2-a]pyridine with selenium
- Mio Matsumura,
- Tsutomu Takahashi,
- Hikari Yamauchi,
- Shunsuke Sakuma,
- Yukako Hayashi,
- Tadashi Hyodo,
- Tohru Obata,
- Kentaro Yamaguchi,
- Yasuyuki Fujiwara and
- Shuji Yasuike
Beilstein J. Org. Chem. 2020, 16, 1075–1083, doi:10.3762/bjoc.16.94
- of UVA-induced stress [17], and bis(2-alkylindol-3-yl) selenides III exhibit antitumor activity toward HT-1080 and MG-22A tumor cell lines [18]. The imidazo[1,2-a]pyridine ring is also an important aromatic heterocycle because its derivatives are biologically active and play an important role in
Graphical Abstract
Figure 1: Biologically active selenides and diselenides having heteroaryl groups.
Figure 2: Ortep drawings of 2a (a and b) and 3a (c and d, thermal elipsoids indicate 50% probability).
Figure 3: The synthesis of bis(2-arylimidazopyridin-3-yl) diselenides. Reaction conditions: 1 (2 mmol), Se (2...
Figure 4: The synthesis of bis(2-arylimidazopyridin-3-yl) selenides. Reaction conditions: 1 (2 mmol), Se (1 m...
Scheme 1: Control reactions.
Scheme 2: Proposed mechanism (1).
Scheme 3: Proposed mechanism (2).
Figure 5: The cytotoxic effect of the bis(2-arylimidazo[1,2-a]pyridin-3-yl) diselenides 2 and selenides 3 on ...
Figure 6: The cytotoxic effect of the bis[2-(4-methoxyphenyl)imidazo[1,2-a]pyridin-3-yl] diselenide 2f on can...
Figure 7: Cytotoxic effect of the bis[2-(4-methoxyphenyl)imidazo[1,2-a]pyridin-3-yl] diselenide 2f on a cance...
Combining enyne metathesis with long-established organic transformations: a powerful strategy for the sustainable synthesis of bioactive molecules
- Valerian Dragutan,
- Ileana Dragutan,
- Albert Demonceau and
- Lionel Delaude
Beilstein J. Org. Chem. 2020, 16, 738–755, doi:10.3762/bjoc.16.68
- highly critical parameter for their activity, while certain alterations of the side chain do not affect the cytotoxicity to a notable extent. Anthramycin In an interesting approach to the protected precursor 8 of (+)-anthramycin (8a), a compound with strong antitumor activity having a
Graphical Abstract
Scheme 1: Intramolecular (A) and intermolecular (B) enyne metathesis reactions.
Scheme 2: Ene–yne and yne–ene mechanisms for intramolecular enyne metathesis reactions.
Scheme 3: Metallacarbene mechanism in intermolecular enyne metathesis.
Scheme 4: The Oguri strategy for accessing artemisinin analogs 1a–c through enyne metathesis.
Scheme 5: Access to the tetracyclic core of nanolobatolide (2) via tandem enyne metathesis followed by an Eu(...
Scheme 6: Synthesis of (−)-amphidinolide E (3) using an intermolecular enyne metathesis as the key step.
Scheme 7: Synthesis of amphidinolide K (4) by an enyne metathesis route.
Scheme 8: Trost synthesis of des-epoxy-amphidinolide N (5) [72].
Scheme 9: Enyne metathesis between the propargylic derivative and the allylic alcohol in the synthesis of the...
Scheme 10: Synthetic route to amphidinolide N (6a).
Scheme 11: Synthesis of the stereoisomeric precursors of amphidinolide V (7a and 7b) through alkyne ring-closi...
Scheme 12: Synthesis of the anthramycin precursor 8 from ʟ-methionine by a tandem enyne metathesis–cross metat...
Scheme 13: Synthesis of (−)‐clavukerin A (9) and (−)‐isoclavukerin A (10) by an enyne metathesis route startin...
Scheme 14: Synthesis of (−)-isoguaiene (11) through an enyne metathesis as the key step.
Scheme 15: Synthesis of erogorgiaene (12) by a tandem enyne metathesis/cross metathesis sequence using the sec...
Scheme 16: Synthesis of (−)-galanthamine (13) from isovanilin by an enyne metathesis.
Scheme 17: Application of enyne metathesis for the synthesis of kempene diterpenes 14a–c.
Scheme 18: Synthesis of the alkaloid (+)-lycoflexine (15) through enyne metathesis.
Scheme 19: Synthesis of the AB subunits of manzamine A (16a) and E (16b) by enyne metathesis.
Scheme 20: Jung's synthesis of rhodexin A (17) by enyne metathesis/cross metathesis reactions.
Scheme 21: Total synthesis of (−)-flueggine A (18) and (+)-virosaine B (19) from Weinreb amide by enyne metath...
Scheme 22: Access to virgidivarine (20) and virgiboidine (21) by an enyne metathesis route.
Scheme 23: Enyne metathesis approach to (−)-zenkequinone B (22).
Scheme 24: Access to C-aryl glycoside 23 by an intermolecular enyne metathesis/Diels–Alder cycloaddition.
Scheme 25: Synthesis of spiro-C-aryl glycoside 24 by a tandem intramolecular enyne metathesis/Diels–Alder reac...
Scheme 26: Pathways to (−)-exiguolide (25) by Trost’s Ru-catalyzed enyne cross-coupling and cross-metathesis [94].
